The pipeline comprises a clinical stage 1/2 in SAH taking advantage of a local administration via the catheter which is installed in order to relieve the intracranial pressure caused by the bleeding. The advantage is that no additional procedures are required and no systemic side effects are expected.
The second project, currently in the research phase, is aimed at broader stroke indications such as global ischemic stroke where the route of administration is intravenous.
